Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in
patients with incurable breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Medivation, Inc. Pfizer
Collaborators:
Astellas Pharma Inc Medivation is now a wholly owned subsidiary of Pfizer Inc. Medivation LLC, a wholly owned subsidiary of Pfizer Inc.